Ignite Creation Date:
2024-05-06 @ 3:27 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04647110
Status:
COMPLETED
Last Update Posted:
2023-04-06
First Post:
2020-11-25
Brief Title:
Real-world Therapy of ALK-positive NSCLC in Sweden the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers
Sponsor:
Pfizer
Organization:
Pfizer
Conditions & Keywords Data
Conditions:
| Name |
|---|
| ALK-positive NSCLC |
Keywords: